Reappoint of Mr. Ravindra Chandrappa, Whole Time Director, who retires by rotation and being eligible offers himself for re-appointment and Continuation of appointment of Mr. Ravikant ....
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anthem Biosciences reported strong FY2026 results with standalone revenue of INR 2,089.31 Crores (up 13.5% from INR 1,840.65 Crores) and consolidated revenue of INR 2,120.35 Crores. Standalone profit after tax grew to INR 570.56 Crores vs INR 506.19 Crores in prior year. The Board recommended a final dividend of INR 2.00 per share (100% payout on face value) for FY2026, payable after shareholder approval at the 20th AGM on July 22, 2026. The company also allotted 14,81,250 equity shares under the Anthem Employee Stock Option Plan 2024, increasing paid-up capital to INR 1,12,63,90,202. On governance, the Board recommended continuation of Mr. Ravikant Uppal as Non-Executive Independent Director upon turning 75, and re-appointment of Mr. Ravindra Chandrappa as Whole Time Director who retires by rotation. Statutory auditors K.P. Rao & Co. issued an unmodified opinion on the financials.
Positive signals include strong revenue and profit growth, consistent dividend payout, and employee stock ownership through ESOPs. The director re-appointments indicate management stability. The company listed on NSE/BSE in July 2025 and this is its first full-year post-IPO results.